Exelixis, Inc. — Form 10-Q summary
Period note: The request metadata says 2021 Q3, but the supplied filing is for the quarter ended September 30, 2022, with comparative figures for 2021. This summary covers the filing provided.
Business context and reporting period
Exelixis is an oncology-focused biotechnology company. Cabozantinib products, principally CABOMETYX, generated the large majority of revenue. The filing reports third-quarter and nine-month results through September 30, 2022.
Financial performance
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Total revenue | $411.7 million | $328.4 million | $1,187.1 million | $983.8 million |
| Net product revenue | $366.5 million | $263.1 million | $1,023.8 million | $774.6 million |
| Operating income | $82.6 million | $51.6 million | $249.6 million | $170.0 million |
| Net income | $73.2 million | $38.2 million | $212.5 million | $135.9 million |
| Diluted EPS | $0.23 | $0.12 | $0.65 | $0.42 |
- Q3 total revenue increased 25% year over year; nine-month revenue increased 21%. Net product revenue rose 39% and 32%, respectively, primarily on higher CABOMETYX unit sales and, to a lesser extent, higher average net selling prices.
- Q3 operating expenses were $329.1 million, including R&D of $198.8 million and SG&A of $115.0 million. For the nine months, operating expenses were $937.6 million, including R&D of $555.0 million and SG&A of $340.6 million.
- Gross margin was 96% in both the quarter and nine-month period, compared with 95% in each 2021 comparison period.
- Operating cash flow for the first nine months was $288.9 million, versus $304.4 million in 2021. Investing cash flow was negative $278.6 million, largely reflecting investment purchases; financing cash flow was positive $2.6 million.
- At September 30, cash, cash equivalents, restricted cash and investments totaled $2.10 billion, versus $1.85 billion at December 31, 2021. Current assets were $1.84 billion and current liabilities $301.7 million; working capital was $1.54 billion.
- The balance sheet reports no borrowings. It includes $159.8 million of long-term operating lease liabilities. Total liabilities were $470.0 million and stockholders’ equity was $2.49 billion.
- Available-for-sale debt securities had $22.3 million of gross unrealized losses, attributed primarily to interest rates and market liquidity rather than credit risk. The filing says management expects to hold the securities long enough for a recovery of cost basis.
Material changes versus the prior comparable period
- Product revenue growth more than offset lower collaboration services revenue: nine-month collaboration services revenue fell to $39.3 million from $92.4 million, mainly reflecting lower development cost reimbursements and the prior-year COSMIC-311 cost-sharing catch-up.
- Nine-month license revenue increased to $124.0 million from $116.9 million, including $25.8 million recognized for 2022 regulatory milestones related to cabozantinib in differentiated thyroid cancer. The prior-year comparison included milestone revenue associated with Takeda’s first Japanese commercial sale of CABOMETYX with OPDIVO.
- R&D expense increased 18% for the nine months, driven mainly by clinical trial costs, personnel and discovery activity. SG&A increased 13%, including higher personnel, marketing, technology and facility costs.
- Interest income rose to $16.1 million for the nine months from $6.2 million, reflecting higher interest rates and investment balances.
- The new 220,517-square-foot Alameda building lease commenced in April 2022. The company recognized a $160.9 million right-of-use asset and a $116.0 million lease liability at commencement.
Outlook, commentary, risks and unusual items
- Management projected net product revenue could increase in the remainder of 2022 versus the corresponding prior-year period, while discounts and allowances as a share of gross revenue could also rise, partly due to greater 340B Program utilization. Management expected collaboration services revenue to decrease and R&D and SG&A expenses to increase for the remainder of 2022.
- Management stated that available cash, investments, product revenue and collaboration revenue were expected to support operations for at least 12 months after filing. It also noted that pipeline investment and business development could require additional capital in the future, although the company believed it had sufficient funds for current and future operating plans.
- In COSMIC-313, the cabozantinib/nivolumab/ipilimumab combination met its primary PFS endpoint versus nivolumab/ipilimumab (hazard ratio 0.73; p=0.01). The interim OS analysis did not show a significant benefit; the trial continues. Based on FDA feedback, Exelixis did not plan to submit an sNDA on the then-available results and expected to discuss a potential submission after the next OS analysis.
- Key commercial risks include competition, payer coverage and reimbursement, drug-pricing initiatives, and potential generic entry for CABOMETYX. MSN and Teva ANDA patent litigation remained pending; the company warned that early generic sales could materially reduce U.S. CABOMETYX revenue. The MSN I bench trial occurred in May 2022, with judgment expected in Q4 2022; the MSN II trial was scheduled for October 2023. Teva proceedings were stayed in October 2022.
- Exelixis disclosed that HHS was reviewing its 340B Program integrity initiative, which requests certain claims-level data from hospital covered entities. The company noted potential risks of required program changes, repayment claims or civil monetary penalties.
- The Inflation Reduction Act may affect future pricing, rebates and revenue; management said the eventual impact was uncertain. COVID-19 had a modest reported operational impact, while the Russo-Ukrainian War posed potential clinical-site, enrollment and supply risks.
- Unusual R&D items included a Q3 reversal of a development milestone previously recorded in 2021 because the compound had not progressed as expected. The company also recorded $9.7 million of Q3 stock-based compensation related to threshold achievement of certain 2020 performance stock units.
- Subsequent to quarter-end, Exelixis announced agreements with Cybrexa and Sairopa involving upfront payments and potential additional milestone and option-exercise payments. These were disclosed as subsequent events, not as Q3 operating results.
Important facts for investors to verify
- Confirm the reporting-period mismatch: the supplied filing is Q3 2022, not Q3 2021.
- Track CABOMETYX sales growth against rising discounts and allowances, particularly 340B exposure and payer policy changes.
- Monitor outcomes and timing in the MSN and Teva patent cases, and assess potential generic-entry implications for the product’s revenue base.
- Review subsequent COSMIC-313 OS results and the progress, enrollment and expense trajectory of XL092 and other pipeline trials.
- Assess investment portfolio interest-rate exposure, the new lease commitments and the funding implications of planned R&D and business-development activity.
- Evaluate the potential effects of the Inflation Reduction Act and HHS review of the 340B integrity initiative as further guidance or outcomes become available.